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Background/aim: Familial Mediterranean Fever (FMF) is the prototype of hereditary autoinflammatory disorders and caused by
mutations on the MEFV gene located on the short arm of chromosome 16. Although some MEFV variants are clearly associated
with disease phenotype, there are numerous variants with unknown clinical association which are termed as variants of uncertain
significance (VUS). Here, we present clinical correlations of VUS in a large cohort of adult FMF patients from three tertiary centers
located in Central Anatolia.
Materials and methods: All patients were recruited from FMF in Central Anatolia (FiCA) cohort. Demographic (sex, age at disease
onset) and clinical features (disease characteristics, attack frequency, mean colchicine dose, colchicine nonresponsiveness, amyloidosis,
and persistent inflammation) of patients with VUS were compared with those harboring pathogenic variants. Disease severity and
damage were also evaluated using international severity score for FMF (ISSF) and autoinflammatory disease damage index (ADDI),
respectively.
Results: Among 971 participants included, MEFV gene analysis results were available for 814 patients. Twenty-six (3.2%) patients had
single heterozygous VUS and 54 (6.6%) had pathogenic/VUS complex heterozygous variants. Patients with single heterozygous VUS
had similar demographic/clinical features, ISSF and ADDI scores compared to those with single heterozygous pathogenic variant (p
> 0.05 for all). No difference was observed in the demographic and clinical features of patients with single heterozygous pathogenic
mutation and pathogenic/VUS complex heterozygous variant (p > 0.05 for all). ISSF and ADDI scores were lower in pathogenic/VUS
complex heterozygous patients than those harboring single pathogenic mutation (p = 0.006 and 0.004, respectively).
Conclusion: Our findings suggest that patients with single heterozygous VUS has mild FMF phenotype similar to those with single
pathogenic mutation. Pathogenic/VUS complex heterozygosity does not lead to a more severe clinical phenotype than having a single
pathogenic variant.
Key words: Familial Mediterranean Fever, MEFV, variants of uncertain significance, genetics, phenotype

1. Introduction
Familial Mediterranean fever (FMF) is the most common
monogenic autoinflammatory disease (AID) worldwide
[1]. Although it has the highest prevalence among people
originated from Eastern Mediterranean, can also be
recognized in subjects from different ethnicities [2–4]. FMF
is caused by mutations in the MEFV gene which is located
on chromosome 16 [5]. MEFV gene is composed of 10
exons and encodes a 781–amino acid protein called pyrin
1

[6]. Pyrin plays a key role in innate immunity and when
mutated, leads to an exaggerated inflammation through
abundant release of interleukin-1β [7]. FMF follows an
autosomal recessive pattern of inheritance, however,
classic phenotypic characteristics may exist in almost 30%
of patients who are single heterozygous [8,9]. To date,
more than 300 variants have been identified within the
MEFV gene region1. These variants are classified as benign,
likely benign, likely pathogenic and pathogenic; according

http://fmf.igh.cnrs.fr/infevers/.
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to their potential association with disease phenotype
with current evidence [10]. However, there are numerous
variants with unknown clinical association which are
termed as variants of uncertain significance (VUS) [10,11].
These variants could be found either homozygous or single
or complex heterozygous. Impact of these variants on final
clinical phenotype and disease complications needs to
be elucidated for proper management of patients. In this
study, we aimed to investigate the clinical significance of
VUS in a large multicenter cohort of Turkish FMF patients
mainly originated from Central Anatolia.
2. Materials and methods
FMF in Central Anatolia (FiCA) is a cross-sectional,
multicenter web-based cohort consisting of adult (≥
18 years old) FMF patients admitted to outpatient
rheumatology departments of three tertiary referral
centers located in central Turkey between January and
December 2018. All recorded patients fulfilled the TelHashomer classification criteria for FMF and had at least
6 months of follow-up [12]. Data obtained from patient
interviews included demographics, disease and treatment
characteristics, comorbidities and disease related
complications. Laboratory, pathologic and genotype
data were collected from hospital records. The diagnosis
of amyloidosis was confirmed with tissue biopsy in all
suspected cases.
2.1. Definitions and patient assessments
Persistent inflammation was defined as an increased
serum C-reactive protein (CRP) levels during the attackfree period (at least 2 weeks apart from attack) and in
more than 75% of follow-up visits was [13]. We defined
colchicine nonresponsiveness as having more than one
attack per month for 3 months duration despite the use of
maximal tolerated dose of colchicine [14].
Disease severity and FMF related damage were
assessed using the international severity score for FMF
(ISSF) [15] and autoinflammatory disease damage index
(ADDI), respectively [16]. Briefly, ISSF consists of nine
clinical and laboratory variables: chronic sequela, organ
dysfunction, organ failure, attack frequency, increased
acute-phase reactants, involvement of more than two sites
during an individual acute attack, more than two different
types of attack during the course of the disease, duration
of attacks, and exertional leg pain. The maximum score
is 10 and the degree of severity was determined as mild
(≤2), intermediate (3–5) or severe disease (≥6) [15]. In
ADDI, damage is defined as “persistent or irreversible
change in structure or function, that is present for more
than 6 months”. ADDI consists 18 items, and these items
are categorized by organ systems as follows: reproductive,
renal/amyloidosis, developmental, serosal, neurological,
2
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ears, ocular and musculoskeletal. The renal/amyloidosis
and neurological damage categories were assigned to have
the highest number of points while serosal damage got
the lowest. This index provides a universal instrument to
measure damage by chronic inflammation in FMF [16].
2.2. Genetic analysis
The MEFV gene variants were genotyped by
pyrosequencing and direct Sanger sequencing techniques.
The 22 common variants profiles; E148Q, R202Q, P369S,
H478Y, F479L, S675N, G678E, M680L, M680I(G>A &
G>C), T681I, I692DEL, M694V, M694I, M694L, K695N,
K695R, I720M, V722M, V726A, A744S, R761H were
genotyped by pyrosequencing. Some patients who had
clinical features without mutated pyrosequencing profiles
were genotyped for exon 10 by direct sequencing analysis.
VUS variants were E148Q, P369S, H478Y, G678E, T681I,
I720M, V722M, A744S. Pathogenic variants were F479L,
M680L, M680I, I692DEL, M694V, M694I, M694L, K695N,
K695R, V726A, and R761H2. Likely pathogenic variants
were classified as pathogenic variant in this study. Patients
were grouped based on different combinations of MEFV
variants in two alleles;
1) Mutation negative (-/-)
2) Single pathogenic (M694V/-, M680I/-, etc.)
3) Single VUS (E148Q/-, A744S/-, etc.)
4) Biallelic (double) pathogenic, homozygous or complex
heterozygous (M694V/M694V, M680I/V726A, etc.)
5) Pathogenic and VUS complex heterozygous
(M694V/E148Q, M680I/A744S etc.).
2.3. Statistical analysis
Statistical analysis was performed using SPSS Statistics for
Windows v: 21.0 (Chicago, IL, USA). Categorical variables
were expressed as number and percentage. Continuous
variables were expressed as mean (standard deviation,
SD) for normally distributed and median (interquartile
range, IQR) for skewed data. Chi-square and Fisher’s exact
test were used to compare categorical data. For normally
distributed continuous variables, Student’s t test was used
to compare the means between two groups and one-way
ANOVA was used to compare the means among 3 groups.
Mann–Whitney U and Kruskal–Wallis tests were used
for comparison of non-normally distributed continuous
data between two and three groups, respectively. We used
Bonferronni correction for posthoc analysis after ANOVA
while intergroup comparisons were performed with
Mann–Whitney U test after Kruskall–Wallis test. In either
condition significance level was set at <0.0167 for posthoc
analysis.
3. Results
Among 971 (61.5% female) FMF patients enrolled in
whole cohort, MEFV gene analysis results could be
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obtained for 814 subjects (60.9% female). Median age at
study enrollment, symptom onset and FMF diagnosis were
34 (25–43), 10 (6–18) and 24 (15–33) years, respectively.
Median disease duration from the onset of symptoms
was 20 (12–29) years. Peritonitis was the most common
clinical feature and present in 90.4% of patients followed
by fever (82.1%), pleuritis (49.0%), arthritis (44.2%),
erysipelas-like erythema or purpuric rash (27.3%), and
myalgia (24.1%). One hundred and twenty-eight (15.7%)
patients had persistently elevated acute phase response
and 50 (6.1%) had amyloidosis. Mean colchicine dose was
1.3 (0.5) mg/day and 72 (8.8%) patients were classified as
colchicine nonresponsive. Median ISSF score was 3 (2–4)
and disease severity categories according to ISSF among
patients were as follows: mild disease in 45.2%, moderate
disease in 47.3% and severe disease in 7.5% of patients.
Using the ADDI index, more than half of patients (n = 482,
59.2%) had disease related damage.
At least one MEFV variant was present in 769 (94.5%)
patients. M694V was the most frequent variant with
being present in 618 (75.9%) patients. 259 (31.8%) and
423 (51.9%) patients had single and biallelic pathogenic
mutations respectively, without harboring any VUS. 26
(3.2%) patients had single VUS (E148Q in 21, A744S in
4 and P369S in 1 patient). VUS and pathogenic complex
heterozygosity was present in 54 (6.6%) patients. Among
these patients, 47 had E148Q and 7 had A744S variant. 3
patients had biallelic VUS; 2 of them had P369S/E148Q
complex heterozygous variant and the other patient had
homozygous E148Q. Allelic frequency of MEFV gene
variants are summarized in Table 1.
No difference in demographics, clinical features, disease
severity, and FMF related damage was observed among
patients with single VUS, single pathogenic mutation, and
no mutation (Table 2). Among 285 subjects with single
MEFV mutation, patients with M694V variant (n = 207)
had more frequent arthritis, persistent inflammation,
and amyloidosis than those without (data not shown).

There was no significant difference for any characteristics
between patients with single VUS and single non-M694V
pathogenic variants (Table 3).
Compared to patients with biallelic pathogenic
mutations, complex heterozygous patients harboring
pathogenic mutation(s) and VUS had older age at disease
onset, lower number of attacks during last year, lower
mean colchicine dose and lower median ISSF and ADDI
scores (Table 4). These patients also less frequently had
pleuritis, arthritis, myalgia, persistent inflammation,
colchicine nonresponsiveness, moderate/severe disease
course, and any disease-related damage than patients
with biallelic pathogenic mutations. Patients with single
pathogenic mutation had higher ISSF and ADDI scores
and more frequently had moderate/severe disease and
disease related damage compared to patients harboring
pathogenic and VUS complex heterozygous variant.
4. Discussion
In the present study, we analyzed the association of
MEFV variants with uncertain significance with clinical
phenotype in a multi-center large cohort consisted of
Turkish patients with FMF. Results of our study disclosed
that patients with single heterozygous VUS variants have a
similar disease course as those with the single pathogenic
variants. Moreover, we found that, complex heterozygous
patients with pathogenic variant and VUS have an
attenuated disease phenotype characterized by milder
disease course and reduced risk of disease complications.
Genetic tests have been implemented in the diagnosis of
autoinflammatory diseases for a long time [17]. However,
despite a few pathogenic variants being intensively studied,
literature data about the genotype-phenotype correlation
of most MEFV variants remain inconclusive. Recently, a
consensus based pathogenicity classification of MEFV
variants was proposed [18]. Although pathogenicity of
some variants agreed by consensus of experts, a large
number of MEFV variants were classified as VUS or

Table 1. Allelic frequencies of common MEFV gene variants excluding mutation
negative subjects (n = 769).
Pathogenic variants

N (%)

VUS variants

N (%)

M694V

844 (54.9)

E148Q

77 (5.0)

M680I

185 (12.0)

P369S

4 (0.3)

V726A

107 (6.9)

A744S

11 (0.7)

R761H

21 (1.4)

F479L

7 (0.4)

K695R

2 (0.1)

VUS; Variants of uncertain significance.
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Table 2. Characteristics of patients with single pathogenic mutation, single VUS and no mutation.
Single
pathogenic
(n = 259)

Single VUS
(n= 26)

Mutation
negative
(n = 45)

p

Female

153 (59.1)

18 (69.2)

30 (66.7)

Age at symptom onset, years

15 (9.0–23.0)

17.5 (10.0–26.2)

Number of attacks during the last year

2 (0–5)

Fever

p1

p2

p3

0.41

0.31

0.82

0.33

15 (8.0–24.5)

0.70

0.41

0.49

0.86

1.5 (0–4)

2 (0–4)

0.50

0.49

0.90

0.30

201 (77.6)

23 (88.5)

33 (73.3)

0.32

0.19

0.13

0.53

Peritonitis

227 (87.6)

23 (88.5)

39 (86.7)

0.97

1.000

1.000

0.85

Pleuritis

96 (37.1)

8 (33.3)

15 (33.3)

0.84

0.71

1.000

0.63

Arthritis

96 (37.1)

5 (20.0)

11 (24.4)

0.07

0.08

0.67

0.09

Myalgia

42 (16.2)

4 (16.7)

6 (13.3)

0.88

1.000

0.73

0.62

Persistent inflammation

24 (9.6)

-

1

0.07

0.14

1.000

0.14

Colchicine dose, mg/d, mean

1.2 (0.5)

1.1 (0.5)

1.1 (0.6)

0.69

0.54

0.86

0.59

Colchicine non-responsiveness

15 (5.8)

1

2

0.87

1.000

1.000

1.000

Amyloidosis

14 (5.4)

0

2

0.46

0.62

0.52

1.000

ADDI score

1 (0–1)

1 (0-1)

1 (0–1)

0.40

0.98

0.34

0.18

Any damage in ADDI

156 (60.2)

16 (61.5)

23 (51.1)

0.49

0.89

0.39

0.25

ISSF

2 (2-3)

2 (1-3)

2 (1-3)

0.12

0.28

0.75

0.06

ISSF category
Mild disease
Moderate/severe disease

139 (53.7)
120 (46.3)

15 (57.7)
11 (42.3)

30 (66.7)
15 (33.3)

0.26

0.45

0.10

0.69

p1; single pathogenic vs. single VUS, p2; single VUS vs. mutation negative, p3; single pathogenic vs. mutation negative.
VUS; Variants of uncertain significance, ADDI; autoinflammatory disease damage index, ISSF; international severity score for FMF.
Values are n (%) and median (Q1–Q3) unless otherwise specified. Significance level was set at 0.0167 in posthoc analysis.

“unsolved pathogenicity”. This highlighted the need for
better characterization of the impact of these variants on
the clinical phenotype.
Vast majority of patients with VUS in our cohort had
E148Q variant which is a prevalent mutation in MEFV
allele [18,19]. Whether E148Q is polymorphism or diseasecausing mutation has been highly debated. Ben-Chetrit et
al. observed similar frequency of E148Q variant both in
patients and healthy controls and concluded E148Q as a
benign polymorphism [20]. The fact that the functional
response evaluated by ex-vivo colchicine assay is similar
between patients with E148Q and healthy controls
expressing wild-type pyrin supports this view [21].
However, some other studies demonstrated that patients
with homozygous E148Q variant may develop FMFlike illness [22]. On the other hand, data about clinical
phenotype of patients with heterozygous E148Q variant is
limited and controversial. Our results showed no difference
in clinical features, disease severity and damage between
patients with single heterozygous pathogenic and single
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heterozygous VUS variants. Most of these similarities,
except arthritis, persisted when patients with heterozygous
VUS were compared with those with single heterozygous
M694V. These results should be carefully interpreted as
there were no patient with amyloidosis in the VUS group
while about 5% of patients with heterozygous pathogenic
variant had amyloidosis. One study on children with
periodic fever and carrying MEFV mutations reported that
patients with heterozygous E148Q or V726A variant less
frequently experienced severe abdominal and chest attacks
compared to those with heterozygous exon 10 mutations
(M694V, M694I, M680I) [23]. More stringent classification
criteria used in our study might have led to selection of
more severe patients with heterozygous VUS variant. In
line with our findings, Kilic et al. reported similar disease
severity between patients harboring heterozygous exon
2 and exon 10 mutations in a cohort of FMF patients
classified according to Tel-Hashomer criteria [24].
Interestingly, patients with pathogenic and VUS
complex heterozygous variant had similar clinical features

SARI et al. / Turk J Med Sci
Table 3. Characteristics of patients harboring single MEFV variant with respect to their potential penetrance.
Single M694V
(n = 207)

Single non-M694V
pathogenic (n = 52)

Single VUS
(n = 26)

p

Age

36.2 (13.1)

36.0 (11.3)

36.1 (10.8)

0.91

Female

121 (58.4)

32 (61.5)

18 (69.2)

0.63

Age at symptom onset, years

15 (10–25)

14 (7–23)

18 (10–26)

0.94

Number of attacks within the last year

2 (0–5)

3 (0–6)

2 (0–4)

0.46

Fever

159 (76.8)

42 (80.8)

23 (88)

0.40

Peritonitis

184 (89)

43 (83)

23 (88)

0.50

Pleuritis

77 (37)

19 (37)

8 (33)

0.97

Arthritis

84 (41)

12 (23)

5 (20)

0.016

Skin rash

41 (20)

1 (2)

2 (8)

0.001

Myalgia

33 (16)

9 (17)

0.96

Persistent inflammation

24 (12)

0

4 (17)
0

Colchicine dose, mg/d, mean

1.2 (0.5)

1.2 (0.4)

1.1 (0.5)

0.71

Colchicine nonresponsiveness

14 (6.8)

1 (1.9)

1 (4)

0.37

Amyloidosis

14 (6.8)

0

0

0.01

ADDI score

1 (0–1)

1 (0–1)

1 (0–1)

0.45

ISSF score

2 (2–3)

3 (2–3)

2 (1–3)

0.70

ISSF severe disease

13 (6.3)

1 (1.9)

0

0.39

0.007

VUS; Variants of uncertain significance, ADDI; autoinflammatory disease damage index, ISSF; international
severity score for FMF.
Values are n (%) and median (Q1–Q3) unless otherwise specified. There was no difference for any characteristics
between single non-M694V and single VUS groups.

with those who had single pathogenic mutation. Moreover,
severity and damage scores were lower in pathogenic and
VUS complex heterozygosity. These findings suggest that
VUS may not have an additive effect on clinical phenotype
when present together with a pathogenic mutation. Very
few studies in the literature provided information about
this issue and had conflicting results mostly focusing
on E148Q which is a relatively frequent variant [25,26].
Occasional reports suggested that E148Q may have an
aggravating effect when present as a part of complex
allele with V726A or M694I [27,28]. On the other hand,
a recent study reported that subjects with exon 10 and
non-exon 10 complex heterozygous variant had similar
clinical features and amyloidosis frequency compared to
patients with single heterozygous mutation [29]. However,
results of that study were not suitable to compare with
ours as single heterozygous group included both VUS
and pathogenic exon 10 mutations. Due to controversial
results in literature, we think in vitro functional studies

are needed to elucidate how VUS genotype contribute to
clinical phenotype when harbored in combination with
clearly pathogenic mutations [21].
This study was conducted in one of the largest adult
FMF cohort with considerable amount of patients with
VUS. Retrospective design and lack of in vitro functional
evaluation are the main limitations to be addressed. Due
to small number of patients in specific VUS variants, we
could not characterize phenotypic effect of each particular
VUS genotype. Small number of patients with VUS other
than E148Q (P396S and A744S) did not allow us to draw
any specific conclusions on these variants and also limited
the generalizability of our results.
In conclusion, harboring a single VUS results in a
mild FMF phenotype similar to those observed in patients
with single heterozygous pathogenic variant. Pathogenic/
VUS complex heterozygosity does not lead to a more
severe clinical phenotype than having single heterozygous
pathogenic variant.
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Table 4. Characteristics of patients with biallelic pathogenic mutation, pathogenic/VUS complex heterozygous mutation and single
pathogenic mutation.
Biallelic pathogenic
Pathogenic and VUS
Single
(homozygous or
complex heterozygous pathogenic
complex heterozygous)
(n = 54)
(n = 259)
(n= 423)

p

p1

p2

Female

259 (61.2)

31 (57.4)

153 (59.1)

0.77

0.58

0.82

Age at symptom onset, years

8 (5–13)

16 (11–25)

15 (9–23)

<0.001

<0.001

0.10

Number of attacks during the last year

3 (1–8)

2 (0–4)

2 (0–5)

0.001

0.040

0.90

Fever

364 (86.1)

42 (77.8)

201 (77.6)

0.008

0.08

0.97

Peritonitis

393 (92.9)

47 (87.0)

227 (87.6)

0.026

0.10

0.90

Pleuritis

258 (61.0)

18 (33.3)

96 (37.1)

<0.001

<0.001

0.66

Arthritis

227 (53.7)

17 (31.5)

96 (37.1)

<0.001

0.002

0.42

Myalgia

135 (31.9)

7 (13.0)

42 (16.2)

<0.001

0.006

0.61

Persistent inflammation

98 (23.2)

5 (9.3)

24 (9.6)

<0.001

0.019

1.000

Colchicine dose, mg/d, mean

1.4 (0.5)

1.0 (0)

1.2 (0.5)

<0.001

<0.001

0.06

Colchicine nonresponsiveness

53 (12.5)

1 (1.9)

15 (5.8)

0.002

0.020

0.32

Amyloidosis

32 (7.6)

2 (3.7)

14 (5.4)

0.36

0.40

1.000

ADDI score

1 (0–2)

0 (0–1)

1 (0-1)

0.001

0.001

0.004

Any damage in ADDI

261 (61.8)

23 (42.6)

156 (60.2)

0.025

0.007

0.017

ISSF

3 (2–4)

2 (1–3)

2 (2–3)

<0.001

<0.001

0.006

ISSF category
Mild disease Moderate/severe disease

141 (33.3)
282 (66.7)

37 (68.5)
17 (31.5)

139 (53.7)
120 (46.3)

<0.001

<0.001

0.045

p1; biallelicpathogenic vs. pathogenic and VUS complex heterozygous, p2; single pathogenic vs. pathogenic and VUS complex
heterozygous.
VUS; Variants of uncertain significance, ADDI; autoinflammatory disease damage index, ISSF; international severity score for FMF.
Values are n (%) and median (Q1–Q3) unless otherwise specified. Significance level was set at 0.0167 in posthoc analysis.
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